Astellas has turned to AstraZeneca for its new senior VP of global development operations.
Eric Terhaerdt spent more than 20 years at AZ, most recently serving as VP, head of scientific and technical evaluations.
He will now lead the global direction of the drug development operations at Japan-based Astellas, working primarily in the Netherlands and the US.
Terhaerdt has extensive knowledge of the global pharmaceutical market having worked across the world for AZ in countries such as the UK, the US, Sweden, Hungary and the Czech Republic.
Dr Bernie Zeiher, executive VP, global development, welcomed Terhaerdt to the company: “His diverse international experience in drug development, strategic planning and change management will help Astellas continue to address the unmet needs of our patients.”